CSK and B-cell chronic lymphocytic leukemia: In a previous study, ibrutinib was found to act on Csk (C-terminal Src kinase) in patients with chronic lymphocytic leukemia (CLL), thereby increasing the risk of off-target cardiotoxicity [89,90].